Piggy-backing the concept of cancer drugs for schistosomiasis treatment: A tangible perspective?

Trends in Parasitology

Volumn 27, Issue 2, 2011, Pages 59-66

  Dissous, Colette ^a   Grevelding, Christoph G ^b  

^a CNRS   (France)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HERBIMYCIN A; IMATINIB; LAPATINIB; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PERIFOSINE; PICEATANNOL; PRAZIQUANTEL; PROTEIN KINASE; RAPAMYCIN; RESVERATROL; SORAFENIB; SUNITINIB; TYRPHOSTIN;

CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DRUG EXPOSURE; EGG PRODUCTION; GASTROINTESTINAL STROMAL TUMOR; HOST PARASITE INTERACTION; HUMAN; IMMUNITY; IN SITU HYBRIDIZATION; KIDNEY CARCINOMA; MITOSIS; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OOCYTE DEVELOPMENT; PARASITE DEVELOPMENT; SCANNING ELECTRON MICROSCOPY; SCHISTOSOMA; SCHISTOSOMIASIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SPERMATOGENESIS; THROMBOCYTOPENIA; TREMATODE LIFE CYCLE STAGE; TWO HYBRID SYSTEM;

ANIMALS; DRUG RESISTANCE; HUMANS; PRAZIQUANTEL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES;

SCHISTOSOMA;

EID: 79251600508     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.09.001     Document Type: Short Survey

References (70)

1. Fenwick A., et al. Implementation of human schistosomiasis control: challenges and prospects. Adv. Parasitol. 2006, 61:567-622.
2. Wang T., et al. Treatment and reinfection of water buffaloes and cattle infected with Schistosoma japonicum in Yangtze River Valley, Anhui province, China. J. Parasitol. 2006, 92:1088-1091.
3. Stothard J.R., et al. Control of schistosomiasis in sub-Saharan Africa: progress made, new opportunities and remaining challenges. Parasitology 2009, 136:1665-1675.
4. Bishop A. Resistance to primaquine in Plasmodium gallinaceum, and the problem of resistance to quinoline compounds in malaria parasites. Parasitology 1967, 57:755-770.
5. Mayers D.L., et al. Antimicrobial Drug Resistance 2009, Humana Press.
6. James C.E., et al. Drug resistance mechanisms in helminths: is it survival of the fittest?. Trends Parasitol. 2009, 25:328-335.
7. Ismail M., et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. 1999, 60:932-935.
8. Sabra A.N., Botros S.S. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure. J. Parasitol. 2008, 94:537-541.
9. Doenhoff M., et al. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 2008, 21:659-667.
10. Black C.L., et al. Impact of intense, longitudinal retreatment with praziquantel on cure rates of Schistosoma mansoni in a cohort of occupationally exposed adults in western Kenya. Trop. Med. Int. Health 2009, 14:450-457.
11. Pica-Mattoccia L., et al. Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. Acta Trop. 2009, 111:82-85.
12. Melman S.D., et al. Reduced susceptibility to Praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl. Trop. Dis. 2009, 3:e504.
13. Messerli S.M., et al. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol. Biochem. Parasitol. 2009, 167:54-59.
14. Hokke C.H., et al. Integrating transcriptome, proteome and glycome analyses of Schistosoma biology. Trends Parasitol. 2007, 23:165-174.
15. Sayed A.A., et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med. 2008, 14:407-412.
16. Abdulla M.H., et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis. 2009, 3:e478.
17. Han Z.G., et al. Schistosoma genomics: new perspectives on schistosome biology and host-parasite interaction. Annu. Rev. Genomics Hum. Genet. 2009, 10:211-240.
18. Kunz W. Schistosome male-female interaction: induction of germ-cell differentiation. Trends Parasitol. 2001, 17:227-231.
19. Ross A.G., et al. Schistosomiasis. N. Engl. J. Med. 2002, 346:1212-1220.
20. Krauss, G. (2008) Biochemistry of Signal Transduction and Regulation (4th edn), Wiley-VCH.
21. Berriman M., et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009, 460:352-358.
22. Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium (2009) The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 460, 345-351.
23. Dissous C., et al. Growth factor receptors in helminth parasites: signalling and host-parasite relationships. FEBS Lett. 2006, 580:2968-2975.
24. Knobloch J., et al. Tyrosine kinase and cooperative TGFβ signaling in the reproductive organs of Schistosoma mansoni. Exp. Parasitol. 2007, 117:318-336.
25. Freitas T.C., et al. TGF-beta signaling controls embryo development in the parasitic flatworm Schistosoma mansoni. PLoS Pathog. 2007, 3:e52.
26. LoVerde P.T., et al. Signal transduction regulates schistosome reproductive biology. Curr. Opin. Microbiol. 2009, 12:422-428.
27. Beckmann S., et al. Schistosoma mansoni: signal transduction processes during the development of the reproductive organs. Parasitology 2010, 137:497-520.
28. Swierczewski B.E., Davies S.J. Developmental regulation of protein kinase A expression and activity in Schistosoma mansoni. Int. J. Parasitol. 2010, 40:929-935.
29. Long T., et al. Schistosoma mansoni Polo-like kinase 1: a mitotic kinase with key functions in parasite reproduction. Int. J. Parasitol. 2010, 40:1075-4086.
30. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14:559-570.
31. Ramachandran H., et al. The Schistosoma mansoni epidermal growth factor receptor homologue, SER, has tyrosine kinase activity and is localized in adult muscle. Mol. Biochem. Parasitol. 1996, 83:1-10.
32. Vicogne J., et al. Conservation of epidermal growth factor receptor function in the human parasitic helminth Schistosoma mansoni. J. Biol. Chem. 2004, 279:37407-37414.
33. Vicogne J., et al. An unusual receptor tyrosine kinase of Schistosoma mansoni contains a Venus Flytrap module. Mol. Biochem. Parasitol. 2003, 126:51-62.
34. Ahier A., et al. A new family of receptor tyrosine kinases with a Venus Flytrap binding domain in insects and other invertebrates activated by amino acids. PLoS ONE 2009, 4:e5651.
35. Khayath N., et al. Diversification of the insulin receptor family in the helminth parasite Schistosoma mansoni. FEBS J. 2007, 274:659-676.
36. You H., et al. Cloning and characterisation of Schistosoma japonicum insulin receptors. PLoS One 2010, 5:e9868.
37. Ahier A., et al. Insulin receptors and glucose uptake in the human parasite Schistosoma mansoni. Parasite 2008, 15:573-579.
38. Knobloch J., et al. Cytological and biochemical evidence for a gonad-preferential interplay of SmFKBP12 and SmTbetaR-I in Schistosoma mansoni. Mol. Biochem. Parasitol. 2004, 138:227-236.
39. Osman A., et al. Schistosoma mansoni TGF-beta receptor II: role in host ligand-induced regulation of a schistosome target gene. PLoS Pathog. 2006, 2:e54.
40. Knobloch J., et al. Herbimycin A suppresses mitotic activity and egg production of female Schistosoma mansoni. Int. J. Parasitol. 2006, 36:1261-1272.
41. Kapp K., et al. The Schistosoma mansoni Src kinase TK3 is expressed in the gonads and likely involved in cytoskeletal organization. Mol. Biochem. Parasitol. 2004, 138:171-182.
42. Kapp K., et al. Identification, isolation and characterization of a Fyn-like tyrosine kinase from Schistosoma mansoni. Parasitology 2001, 122:317-327.
43. Bahia D., et al. Schistosoma mansoni: expression of Fes-like tyrosine kinase SmFes in the tegument and terebratorium suggests its involvement in host penetration. Exp. Parasitol. 2007, 116:225-232.
44. Beckmann S., et al. The Syk kinase SmTK4 of Schistosoma mansoni is involved in the regulation of spermatogenesis and oogenesis. PLoS Pathog. 2010, 6:e1000769.
45. Beckmann S., Grevelding C.G. Imatinib makes a fatal impact on morphology, pairing stability, and survival of adult S. mansoni in vitro. Int. J. Parasitol. 2010, 40:521-526.
46. Futreal P.A., et al. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
47. Stratton M.R., et al. The cancer genome. Nature 2009, 458:719-724.
48. Lord C.J., Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol. 2010, 8:38.
49. Wen W., et al. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 2009, 59:111-137.
50. Johnson L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 2009, 42:1-40.
51. Stegmeier F., et al. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 2010, 87:543-552.
52. Mross K., et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26:5511-5517.
53. Renner A.G., et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009, 114:659-662.
54. Wäsch R., et al. BI 2536 - targeting the mitotic kinase Polo-like kinase 1 (Plk1). Recent Results Cancer Res. 2010, 184:215-218.
55. Okabe M., Uehara M. New insight into oncoprotein-targeted antitumor effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells. Leuk. Lymphoma 1993, 12:41-49.
56. Kaminska B., et al. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim. Pol. 2005, 52:329-337.
57. Geahlen R.L., McLaughlin J.L. Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 1989, 165:241-245.
58. Roupe K.A., et al. Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 2006, 1:81-101.
59. Farrow B., et al. Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery 2003, 134:197-205.
60. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1031-1037.
61. Waller C.F. Imatinib mesylate. Recent Results Cancer Res. 2010, 184:3-20.
62. Stelma F.F., et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 1995, 53:167-170.
63. Dissous C., et al. Protein tyrosine kinases as new potential targets against human schistosomiasis. Bioessays 2007, 29:1281-1288.
64. Doerig C., et al. Malaria: targeting parasite and host cell kinomes. Biochim. Biophys. Acta 2010, 1804:604-612.
65. Jirage D., et al. Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect. Disord. Drug. Targets 2010, 10:134-146.
66. zur Hausen H. The search for infectious causes of human cancers: where and why (Nobel lecture). Angew. Chem. Int. Ed. Engl. 2009, 48:5798-5808.
67. Mayer D.A., Fried B. The role of helminth infections in carcinogenesis. Adv. Parasitol. 2007, 65:239-296.
68. Vennervald B.J., Polman K. Helminths and malignancy. Parasite Immunol. 2009, 31:686-696.
69. Nzila A., et al. Anticancer agents against malaria: time to revisit?. Trends Parasitol. 2010, 26:125-129.
70. Chaturvedi D., et al. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem. Soc. Rev. 2010, 39:435-454.